C-UPKCRION
platelet-derived exosomes, PEP, drug delivery
repairingextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-UPKC
C-UPKCC-UPKCplatelet-derived exosomes, PEP, drug delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
RION platelet-derived exosomes, PEP, drug delivery
RION is a clinical-stage regenerative medicine company based in Rochester, MN, established out of the Mayo Clinic Employee Entrepreneurial Program in 2017. The company has isolated a unique platelet-derived exosome phenotype called Purified Exosome Product or PEP™, discovered at the Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program. RION has built a proprietary platform focused on PEP™ mode of action, scaled exosome manufacturing, therapeutic applications, and exosome-based delivery of mRNA, siRNA, DNA, and small molecules.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
RION — Translational · Bottom quartile. Derived deterministically from 9 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (3 programs at…
Source: Deterministic